AZ Exercises Caution With COVID Vaccine Safety Pause As Questions Remain Over Vector
Pause Affects All AZD1222 Trials
The clinical pause for AZD1222 errs on the side of caution, but raises questions about the viral vector’s safety.
You may also be interested in...
Join us for a quick audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
The president of Takeda’s global vaccines business emphasizes the need to build trust and ensure that pharma is transparent about “what we will and will not know” at the time that COVID-19 vaccines are licensed.
While AZ awaits an independent review, its CEO maintains the vaccine could soon be back on track for a late 2020/early 2021 approval.